Intriguingly, the extracellular domain of ActRIIA stabilized by fusion to IgG-Fc increases bone mass and strength by activin inhibition, and is a novel promising agent for osteoporosis in early human trials [77,78] (Table S2; Additional file 2). This evidence concerns the gene ACVR2A and osteoporosis.